PMID- 36372774
OWN - NLM
STAT- MEDLINE
DCOM- 20230112
LR  - 20230209
IS  - 1096-9071 (Electronic)
IS  - 0146-6615 (Print)
IS  - 0146-6615 (Linking)
VI  - 95
IP  - 1
DP  - 2023 Jan
TI  - Varicella zoster virus reactivation following COVID-19 vaccination in patients 
      with autoimmune inflammatory rheumatic diseases: A cross-sectional Chinese study 
      of 318 cases.
PG  - e28307
LID - 10.1002/jmv.28307 [doi]
LID - e28307
AB  - Recently, varicella-zoster virus (VZV) reactivation has been observed after the 
      administration of coronavirus disease 2019 (COVID-19) vaccines. Autoimmune 
      inflammatory rheumatic diseases (AIIRDs) patients are at a higher risk for VZV 
      reactivation for immunocompromised status. The study aimed to investigate the 
      adverse events (AEs), especially VZV reactivation, following vaccination against 
       severe acute respiratory syndrome coronavirus-2 in a Chinese cohort of AIIRD 
      patients. A cross-sectional survey using an online questionnaire was conducted 
      among AIIRD patients and healthy controls (HCs). Multivariate logistic regression 
      was used to identify potential factors associated with VZV reactivation. 318 
      AIIRD patients and 318 age and sex-matched HCs who got COVID-19 inactivated 
      vaccines were recruited. The main AIIRDs are rheumatoid arthritis (31.8%) and 
      systemic lupus erythematous (23.9%). Most of patients (85.5%) had stable disease 
      and 13.2% of them had aggravation after vaccination. Compared to HCs, patients 
      had higher rates of rash (p = 0.001), arthralgia (p < 0.001) and insomnia 
      (p = 0.007). In addition, there were 6 (1.9%) AIIRD patients and 5 (1.6%) HCs 
      reported VZV reactivation after the COVID-19 vaccination (p = 0.761). 
      Multivariate logistic regression analysis illustrated that diabetes mellitus (odd 
      ratio [OR], 20.69; 95% confidence interval [CI], 1.08-396.79; p = 0.044), chronic 
      hepatitis B virus infection (OR, 24.34; 95% CI, 1.27-466.74; p = 0.034), and 
      mycophenolate mofetil (OR, 40.61; 95% CI, 3.33-496.15; p = 0.004) independently 
      identified patients with VZV reactivation. Our findings showed that the 
      inactivated COVID-19 vaccination was safe for AIIRD patients though some patients 
      could suffer from VZV reactivation.
CI  - (c) 2022 The Authors. Journal of Medical Virology published by Wiley Periodicals 
      LLC.
FAU - Chen, Jiali
AU  - Chen J
AD  - Department of Rheumatology and Immunology, The Second Xiangya Hospital, Central 
      South University, Changsha, Hunan, China.
FAU - Li, Fen
AU  - Li F
AD  - Department of Rheumatology and Immunology, The Second Xiangya Hospital, Central 
      South University, Changsha, Hunan, China.
FAU - Tian, Jing
AU  - Tian J
AD  - Department of Rheumatology and Immunology, The Second Xiangya Hospital, Central 
      South University, Changsha, Hunan, China.
FAU - Xie, Xi
AU  - Xie X
AD  - Department of Rheumatology and Immunology, The Second Xiangya Hospital, Central 
      South University, Changsha, Hunan, China.
FAU - Tang, Qi
AU  - Tang Q
AD  - Department of Rheumatology and Immunology, The Second Xiangya Hospital, Central 
      South University, Changsha, Hunan, China.
FAU - Chen, Yiyue
AU  - Chen Y
AD  - Department of Rheumatology and Immunology, The Second Xiangya Hospital, Central 
      South University, Changsha, Hunan, China.
FAU - Ge, Yan
AU  - Ge Y
AUID- ORCID: 0000-0003-4378-6990
AD  - Department of Rheumatology and Immunology, The Second Xiangya Hospital, Central 
      South University, Changsha, Hunan, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20221121
PL  - United States
TA  - J Med Virol
JT  - Journal of medical virology
JID - 7705876
RN  - 0 (COVID-19 Vaccines)
SB  - IM
MH  - Humans
MH  - *COVID-19/prevention & control
MH  - *COVID-19 Vaccines/adverse effects
MH  - Cross-Sectional Studies
MH  - *Hepatitis B, Chronic
MH  - *Herpes Zoster/epidemiology
MH  - Herpesvirus 3, Human
MH  - *Rheumatic Diseases
MH  - Vaccination/adverse effects
PMC - PMC9878204
OTO - NOTNLM
OT  - COVID-19 vaccine
OT  - SARS coronavirus
OT  - autoimmune inflammatory rheumatic diseases
OT  - varicella-zoster virus reactivation
COIS- The authors declare no conflict of interest.
EDAT- 2022/11/14 06:00
MHDA- 2023/01/11 06:00
PMCR- 2022/11/21
CRDT- 2022/11/13 22:32
PHST- 2022/10/27 00:00 [revised]
PHST- 2022/08/30 00:00 [received]
PHST- 2022/11/10 00:00 [accepted]
PHST- 2022/11/14 06:00 [pubmed]
PHST- 2023/01/11 06:00 [medline]
PHST- 2022/11/13 22:32 [entrez]
PHST- 2022/11/21 00:00 [pmc-release]
AID - JMV28307 [pii]
AID - 10.1002/jmv.28307 [doi]
PST - ppublish
SO  - J Med Virol. 2023 Jan;95(1):e28307. doi: 10.1002/jmv.28307. Epub 2022 Nov 21.